Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma

Lung Cancer

Volumn 88, Issue 1, 2015, Pages 9-15

  Wieckowski, Sébastien ^a   Hemmerle, Teresa ^b,c   Prince, Spasenja Savic ^d   Schlienger, Béatrice Dolder ^a   Hillinger, Sven ^e   Neri, Dario ^b,c   Zippelius, Alfred ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c PHILOCHEM AG   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CD8 T cells; Human; Immunocytokine; Immunofluorescence; Lung cancer; Mouse

Indexed keywords

F8 INTERLEUKIN 2 IMMUNOCYTOKINE; FIBRONECTIN; IMMUNOCYTOKINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; F8-IL2 IMMUNOCYTOKINE; HYBRID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY STRUCTURE; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL TRANSFER; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; LUNG ADENOCARCINOMA; LUNG BIOPSY; METASTASIS; MICROENVIRONMENT; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY T LYMPHOCYTE; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING; IMMUNOLOGY; LUNG NEOPLASMS; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS;

EID: 84924595179     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.01.019     Document Type: Article

References (37)

1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
2. Rangachari D., Brahmer J.R. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol 2013, 14:580-594.
3. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
4. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
5. Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther 2008, 8:1495-1505.
6. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141.
7. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998, 338:1272-1278.
8. Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998, 228:307-319.
9. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210:474-484. Discussion 484-475.
10. Siegel J.P., Puri R.K. Interleukin-2 toxicity. J Clin Oncol 1991, 9:694-704.
11. Den Otter W., Dobrowolski Z., Bugajski A., Papla B., Van Der Meijden A.P., Koten J.W., et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 1998, 159:1183-1186.
12. Bubeník J., Den Otter W., Huland E. Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol Immunother 2000, 49:116-122.
13. Pasche N., Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012, 17:583-590.
14. Neri D., Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005, 5:436-446.
15. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010, 28:585-593.
16. Singh M., Murriel C.L., Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Can Res 2012, 72:2695-2700.
17. Hemmerle T., Probst P., Giovannoni L., Green A.J., Meyer T., Neri D. The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer 2013, 109:1206-1213.
18. Pedretti M., Soltermann A., Arni S., Weder W., Neri D., Hillinger S. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 2009, 64:28-33.
19. Villa A., Trachsel E., Kaspar M., Schliemann C., Sommavilla R., Rybak J.N., et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008, 122:2405-2413.
20. DuPage M., Dooley A.L., Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009, 4:1064-1072.
21. Mosmann T.R., Yokota T., Kastelein R., Zurawski S.M., Arai N., Takebe Y. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol 1987, 138:1813-1816.
22. Yokota T., Arai N., Lee F., Rennick D., Mosmann T., Arai K. Use of a cDNA expression vector for isolation of mouse interleukin 2 cDNA clones: expression of T-cell growth-factor activity after transfection of monkey cells. Proc Natl Acad Sci U S A 1985, 82:68-72.
23. Borsi L., Balza E., Carnemolla B., Sassi F., Castellani P., Berndt A., et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102:4384-4392.
24. Moschetta M., Pretto F., Berndt A., Galler K., Richter P., Bassi A., et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 2012, 72:1814-1824.
25. Castellani P., Viale G., Dorcaratto A., Nicolo G., Kaczmarek J., Querze G., et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618.
26. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94:275-280.
27. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
28. DuPage M., Cheung A.F., Mazumdar C., Winslow M.M., Bronson R., Schmidt L.M., et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19:72-85.
29. Ryffel B., Mihatsch M.J., Woerly G. Pathology induced by interleukin-6. Int Rev Exp Pathol 1993, 34(Pt A):79-89.
30. Ma Y., Conforti R., Aymeric L., Locher C., Kepp O., Kroemer G., et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011, 30:71-82.
31. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.-I., Antonia S., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010, 120:1111-1124.
32. Kaneno R., Shurin G.V., Tourkova I.L., Shurin M.R. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009, 7:58.
33. Gutbrodt K.L., Casi G., Neri D. Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 2014, 13:1772-1776.
34. Ahmadzadeh M., Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107:2409-2414.
35. Scarpino S., Stoppacciaro A., Pellegrini C., Marzullo A., Zardi L., Tartaglia F., et al. Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid. J Pathol 1999, 188:163-167.
36. Brack S.S., Silacci M., Birchler M., Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208.
37. Pini A., Viti F., Santucci A., Carnemolla B., Zardi L., Neri P., et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273:21769-21776.